Peer Review History

Original SubmissionJuly 28, 2022
Decision Letter - Tariq Jamal Siddiqi, Editor

PONE-D-22-20412Efficacy and safety of vapocoolant spray for vascular puncture in children and adults: a systematic review and meta-analysisPLOS ONE

Dear Dr. Qu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. Thank you for stating the following financial disclosure:

"NO"

At this time, please address the following queries:

a)        Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b)        State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c)        If any authors received a salary from any of your funders, please state which authors and which funders.

d)        If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in your Competing Interests section: 

“There was no competing interests.”

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

 This information should be included in your cover letter; we will change the online submission form on your behalf.

5. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

6. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Wang et al. conducted a meta-analysis on “Efficacy and safety of vapocoolant spray for vascular puncture in children and adults”, and found that vapocoolant spray was effective in reducing pain from vein puncture in adults, carried no significant adverse effects, and had a positive impact on patient’s attitude towards future use of the spray. However, it was not found to be effective in reducing pain in children, in arterial puncture, and increased the difficulty of the vascular access procedures. In my opinion, certain edits are still required:

1. In the abstract, the authors need to mention that the analysis was performed using random-effects model with risk ratios and mean differences.

2. In line 53-54 please replace the phrase “This procedure is painful, easy to increase….” With “This procedure is painful, which might increase the anxiety levels in patients and may lead to development of needle fear”.

3. In line 55 the percentage of prevalence of needle fear among children can be mentioned.

4. Authors should rephrase line 56-57 to make better sense of what they are trying to depict.

5. The paragraphs under eligibility criteria and study selection could be merged under one heading.

6. For the outcome pain intensity, authors need to pool effect sizes from all possible studies irrespective of the risk of bias an individual study carries. To enhance the reliability of the result, a sub-group analysis could be performed comparing low or moderate risk studies with high risk studies.

7. In the discussion section authors should talk how their findings are relevant and what do they add to the existing literature. Clinical implications also need to be included.

8. Line 362-368 should be mentioned in the limitations section.

9. The outcome procedural difficulty is an integral part of the meta-analysis and should be mentioned in the conclusion section.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Editor,

Thank you very much for giving us an opportunity to revise our manuscript. We appreciate editor and reviewers very much for their positive and constructive comments and suggestions on our manuscript entitled “Efficacy and safety of vapocoolant spray for vascular puncture in children and adults: a systematic review and meta-analysis” (ID: PONE-D-22-20412).

A point-by-point response to the reviewer's comments, a tracked version of the manuscript using the 'Track Changes' function in MS Word, and a clean version of the manuscript with all changes accepted are all submitted. Meanwhile, we checked the whole article carefully to revise possible editing and punctuation mistakes. We hope you are satisfied with our revised manuscript. Our replies to the comments of the reviewers are attached below.

At the same time, we ensure that our manuscript meets PLOS ONE's style requirements. At your suggestion we have made detail and repeated revisions for possible linguistic errors. The corresponding authors’ ORCID ID is 0000-0002-4281-2985, we have updated it in ‘Update my Information’. We have amended statements in the cover letter about funding, Data Availability and competing Interests.

We would like to express our great appreciation to you and reviewers for comments on our paper. Looking forward to hearing from you.

Thank you and best regards.

Your sincerely,

Corresponding author

Quiyu Qu

Our Reply to the reviewer's Comments:

Reviewer#1' Comments to Author:

Wang et al. conducted a meta-analysis on “Efficacy and safety of vapocoolant spray for vascular puncture in children and adults”, and found that vapocoolant spray was effective in reducing pain from vein puncture in adults, carried no significant adverse effects, and had a positive impact on patient’s attitude towards future use of the spray. However, it was not found to be effective in reducing pain in children, in arterial puncture, and increased the difficulty of the vascular access procedures. In my opinion, certain edits are still required

Dear Reviewer,

Thank you very much for your time spent in reviewing our manuscript and for your encouraging comments on its merits. After careful consideration, we have further revised the article. We hope that you will be more satisfied with the revised version.

1. In the abstract, the authors need to mention that the analysis was performed using random-effects model with risk ratios and mean differences.

Reply from authors: Thank you very much for your valuable suggestion. We agree with you very much. We have added the information in the manuscript.

[Relative revision can be found in the abstract part, line 34-36]

2. In line 53-54 please replace the phrase “This procedure is painful, easy to increase….” With “This procedure is painful, which might increase the anxiety levels in patients and may lead to development of needle fear”.

Reply from authors: Thank you for your good advice. Your suggestions really mean a lot to us. According to your suggestion, we have replaced the phrase. Thank you very much.

[Relative revision can be found in the Induction part, line 59-60]

3. In line 55 the percentage of prevalence of needle fear among children can be mentioned.

Reply from authors: Thank you very much for your valuable suggestion. This suggestion is very important for us, and we have added the percentage of prevalence of needle fear among children.

[Relative revision can be found in the Induction part, line 61]

4. Authors should rephrase line 56-57 to make better sense of what they are trying to depict.

Reply from authors: Thanks for your valuable comments. It's a great help for us to have your suggestions. Through consideration and literature review, we modified the problem in the revised manuscript: Existing studies have demonstrated that these negative experiences of needle puncture can not only increase the experience of pain through psychological and physiological mechanisms [3-5], but can also decrease patient compliance and make it more difficult for medical personnel to perform the procedure. Thank you very much.

[Relative revision can be found in the Induction part, line 62-65]

5. The paragraphs under eligibility criteria and study selection could be merged under one heading.

Reply from authors: Thank you very much for your valuable suggestion. We have merged Data extraction and quality assessment under one heading.

[Relative revision can be found in the Materials and Methods part, line 128-140]

6. For the outcome pain intensity, authors need to pool effect sizes from all possible studies irrespective of the risk of bias an individual study carries. To enhance the reliability of the result, a sub-group analysis could be performed comparing low or moderate risk studies with high risk studies.

Reply from authors: Thank you very much for your valuable suggestion. This suggestion is very important for us. We have examined and revised the section of Pain scores after Intravenous cannulation. Thank you very much again for your valuable suggestion and understanding.

[Relative revision can be found in the Materials and Methods part, line 233-249]

7. In the discussion section authors should talk how their findings are relevant and what do they add to the existing literature. Clinical implications also need to be included.

Reply from authors: Thanks for your valuable comments. It's a great help for us to have your suggestions. We have added the information in the manuscript. Thank you very much.

[Relative revision can be found in the Discussion part, line 353-356, 372-375]

8. Line 362-368 should be mentioned in the limitations section.

Reply from authors: Thank you very much for your valuable suggestion. We have amended this section to the limitations section.

[Relative revision can be found in the limitations part, line 392-395]

9. The outcome procedural difficulty is an integral part of the meta-analysis and should be mentioned in the conclusion section.

Reply from authors: Thank you very much for your valuable suggestion. We have added the information in the manuscript.

[Relative revision can be found in the Conclusions part, line 402-405]

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Tariq Jamal Siddiqi, Editor

Efficacy and safety of vapocoolant spray for vascular puncture in children and adults: a systematic review and meta-analysis

PONE-D-22-20412R1

Dear Dr. Qu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Tariq Jamal Siddiqi, Editor

PONE-D-22-20412R1

Efficacy and safety of vapocoolant spray for vascular puncture in children and adults: a systematic review and meta-analysis

Dear Dr. Qu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .